Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL: Obinutuzumab + Pixantrone in Relapsed Aggressive B-cell Lymphoma
NCT02499003Phase 2Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Aug 2015
- Primary completion
- Jan 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), transformed indolent lymphoma (TIL), sponsored by Johannes Gutenberg University Mainz. Started Aug 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)transformed indolent lymphoma (TIL)
Beyond the preview
Go deeper on NCT02499003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499003.